These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 39399879)

  • 21. Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics.
    Alphs L; Bossie CA; Sliwa JK; Fu DJ; Ma YW; Hulihan J
    Neuropsychiatr Dis Treat; 2013; 9():341-50. PubMed ID: 23493643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study.
    Nasser AF; Henderson DC; Fava M; Fudala PJ; Twumasi-Ankrah P; Kouassi A; Heidbreder C
    J Clin Psychopharmacol; 2016 Apr; 36(2):130-40. PubMed ID: 26862829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone.
    Nasrallah HA; Duchesne I; Mehnert A; Janagap C; Eerdekens M
    J Clin Psychiatry; 2004 Apr; 65(4):531-6. PubMed ID: 15119916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paliperidone palmitate for schizophrenia.
    Nussbaum AM; Stroup TS
    Cochrane Database Syst Rev; 2012 Jun; (6):CD008296. PubMed ID: 22696377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.
    Harlin M; Yildirim M; Such P; Madera-McDonough J; Jan M; Jin N; Watkin S; Larsen F
    CNS Drugs; 2023 Apr; 37(4):337-350. PubMed ID: 36961650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.
    Kane JM; McEvoy JP; Correll CU; Llorca PM
    CNS Drugs; 2021 Nov; 35(11):1189-1205. PubMed ID: 34636025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study.
    Iwata N; Ishigooka J; Naoi I; Matsumoto M; Kanamori Y; Nakamura H; Higuchi T
    CNS Drugs; 2020 Jan; 34(1):103-116. PubMed ID: 31883082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT.
    Howard R; Cort E; Bradley R; Harper E; Kelly L; Bentham P; Ritchie C; Reeves S; Fawzi W; Livingston G; Sommerlad A; Oomman S; Nazir E; Nilforooshan R; Barber R; Fox C; Macharouthu A; Ramachandra P; Pattan V; Sykes J; Curran V; Katona C; Dening T; Knapp M; Romeo R; Gray R
    Health Technol Assess; 2018 Nov; 22(67):1-62. PubMed ID: 30507375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
    Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
    Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
    Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
    Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients.
    Petrić D; Rački V; Gačo N; Kaštelan A; Graovac M
    J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):197-204. PubMed ID: 30758986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.
    Möller HJ
    Drugs; 2007; 67(11):1541-66. PubMed ID: 17661527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability - a review.
    González-Rodríguez A; Catalán R; Penadés R; Garcia-Rizo C; Bioque M; Parellada E; Bernardo M
    Patient Prefer Adherence; 2015; 9():695-706. PubMed ID: 26082620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
    Fleischhacker WW; Eerdekens M; Karcher K; Remington G; Llorca PM; Chrzanowski W; Martin S; Gefvert O
    J Clin Psychiatry; 2003 Oct; 64(10):1250-7. PubMed ID: 14658976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.